An observational study in Liver Ablation, Liver Cancer and Liver Cancer (Primary and Metastatic), sponsored by Varian, a Siemens Healthineers Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Varian, a Siemens Healthineers Company (part of Siemens Healthineers) · Observational
This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time.
This study is a retrospective multi-center registry designed to evaluate the safety and performance of the Intelliblate Microwave Ablation (MWA) System with dual channel simultaneous microwave ablation of the liver.
1,345 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
This study's planned enrollment of 63 is below the median of 200 across 342 observational studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →Varian, a Siemens Healthineers Company is the lead sponsor of 29 studies on the registry; 8 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
First submitted after Varian became part of Siemens Healthineers.
Counted across the registry records on this site, refreshed daily.
Subjects will have undergone at least one dual channel MWA treatment in the liver using the Intellblate MWA system and have at least 30 days of follow-up for safety and 8 weeks (-4 weeks, +8 weeks) follow-up for complete ablation evaluation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will have undergone at least one dual channel MWA treatment in the liver using the Intellblate MWA system
30-Day Major Complication Rate
30-day post-treatment Major Complication Rate (Grade 3 or above) according to CTCAE criteria. This evaluates the safety of the IntelliBlate MWA System using dual-channel simultaneous microwave ablation of the liver.
Time frame: Treatment to 30 days of follow-up
Complete Ablation Rate
Complete Ablation Rate based on post-procedure imaging. This evaluates the performance/effectiveness of the IntelliBlate MWA System.
Time frame: 8 weeks post-treatment, with an allowable window of -4 weeks to +8 weeks
No study locations are listed for this record.
Plan to share: Undecided — Individual participant data could be shared with each site for their own patients upon request.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Varian, a Siemens Healthineers Company →